NSE · Healthcare · Drug Manufacturers - Specialty & Generic
| Document | Date |
|---|---|
| Q1 FY27 earnings call ZIM LABORATORIES LIMITED - Q1 FY27 SUMMARY HEADLINE NUMBERS • Total operating income: INR 942 million, representing 31.2% YoY growth • EBITDA: INR 3 | 2026-08-12 |
| Investor presentation · Q1 FY27 ZIM LABORATORIES LIMITED – Q1 FY27 SUMMARY HEADLINE NUMBERS • Total Operating Income: ₹942 Mn, up 31.2% YoY (vs ₹718 Mn in Q1 FY26); down 10.5% QoQ | 2026-08-06 |
| Quarterly results · Q1 FY27 ZIM LABORATORIES LIMITED – Q1 FY2026-27 RESULTS SUMMARY HEADLINE NUMBERS • Q1 FY2026-27 Revenue from Operations (Consolidated): Rs 9,417.85 lakhs – | 2026-08-06 |
| Annual report FY2026 ZIM LABORATORIES LIMITED – FY26 SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Total Operating Income: ₹3,744 Mn – essentially flat vs FY25 (₹3,790 | 2026-06-05 |
| Q4 FY26 earnings call ZIM LABORATORIES LIMITED – Q4 FY26 EARNINGS SUMMARY HEADLINE NUMBERS • FY26 Total Operating Income: INR 3,744 million (broadly flat vs FY25) • FY26 | 2026-05-23 |
| Quarterly results · Q4 FY26 ZIM LABORATORIES LIMITED – FINANCIAL SUMMARY HEADLINE NUMBERS • Total Income FY 2026: Rs. 38,578.31 lakhs (vs. Rs. 38,481.51 lakhs in FY 2025) • Rev | 2026-05-19 |
| Q3 FY26 earnings call ZIM LABORATORIES LIMITED - Q3 & 9M FY26 EARNINGS SUMMARY HEADLINE NUMBERS • Q3 FY26 Total Operating Income: INR 1,087 million (improved sequentially | 2026-02-17 |
| Quarterly results · Q3 FY26 ZIM LABORATORIES LIMITED – FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS CONSOLIDATED RESULTS (9 MONTHS ENDED 31 DECEMBER 2025) • Revenue from operatio | 2026-02-11 |
Readable in the app.
| Announcement | Date |
|---|---|
| Acquisition of another business or strategic stake Zim Laboratories Limited has informed the Exchange about Acquisition - General Updates | 2026-04-09 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Zim Laboratories Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.